Protocol: L043M
______________________________________________________________________________
| 584 |L01XC02| RITUXIMABUM**** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L01XC02 RITUXIMABUM CONC. PT. SOL. PERF. 10 mg/ml
MABTHERA 100 mg 10 mg/ml ROCHE REGISTRATION LTD.
MABTHERA 500 mg 10 mg/ml ROCHE REGISTRATION LTD.
________________________________________________________________________________
______________________________________________________________________________
| 585 |L04AA11| ETANERCEPTUM**** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA11 ETANERCEPTUM PULB. + SOLV. PT. 25 mg
SOL. INJ.
ENBREL 25 mg 25 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM PULB + SOLV. PT. 50 mg
SOL. INJ.
ENBREL 50 mg 50 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM PULB. + SOLV. PT. 25 mg
SOL. INJ.
ENBREL 25 mg 25 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM PULB + SOLV. PT. 50 mg
SOL. INJ.
ENBREL 50 mg 50 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM SOL. INJ. ÎN SERINGĂ 25 mg
PREUMPLUTĂ
ENBREL 25 mg 25 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM SOL. INJ. ÎN SERINGĂ 50 mg
PREUMPLUTĂ
ENBREL 50 mg 50 mg WYETH EUROPA LIMITED
________________________________________________________________________________
______________________________________________________________________________
| 586 |L04AA12| INFLIXIMABUM**** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA12 INFLIXIMABUM PULB. PT. CONC. 100 mg
PT. SOL. PERF.
REMICADE 100 mg 100 mg CENTOCOR B.V.
________________________________________________________________________________
______________________________________________________________________________
| 587 |L04AA17| ADALIMUMABUM**** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA17 ADALIMUMABUM SOL. INJ. ÎN SERINGĂ 40 mg
PREUMPLUTĂ
HUMIRA 40 mg 40 mg ABBOTT LABORATORIES LTD.
SUBLISTA C1 - G31C ARTROPATIA PSORIAZICA.
Dostları ilə paylaş: |